Professional Documents
Culture Documents
et al : Myelodisplastic syndrome in
1985.
9. Yunis JJ, Lobell M, Arnesen MA, et al :
The
Myelodisplastic
with
Haematol 98:189,1988.
10. Paydas S, Zorludemir S : Leukemia
2003:2077-2093.
3. Silverman LR, Demakos EP Peterson
BL et al : Randomized Controlled Triad
of Azaticidine in Patients with the
Myelodysplastic Syndromes : a study of
cancer and the leukemia group B. J Clin
Oncol 20:2429-2440,2002.
4. Fouchar K , Langdon RM II ArmitagoJO,
Olson DB, Carrol TJ Jr: Myelodysplastic
Syndromes:
clinical
pathologic
Prognostic
Factor
in
the
myelodysplastic
syndrome
and
syndromes
and
and
syndromes
with
myelodysplastic
(7;9)
chromosome
R,
Belzer
M,
Miller
patients
with
syndromes
immunosuppressive
myelodysplastic
response
therapy.
to
Br
C,
histological
findings
myelodysplastic
additional
of
the
scoring
systems.
syndromes
in
and
101
cases
according
to
the
FAB
localization
of
immature
associations
with
myelodysplastic
al.:
myelodysplastic
syndromes
morphological,
cytochemical
15:927-939, 1984.
17. Tani K, Fujii H, Takahashi K, et al :
Erythrocyte
enzyme
activities
in
Abnormal
granulocytes
immunocytochemical
study
in
:
A
and
of
71
30:97, 1989.
18. Breton Gorius J, Houssay D, Dreyfus
refractory
anaemia.
Br
evaluations
erythropoiesis
myelodysplastic
in
of
patient
with
syndromes.
Acta
Haematol 79:81,1988.
22. Peters RE, May A, Jacobs A : Increased
Alpha:non-alpha globin chain synthesis
ratio in myelodysplastic syndromes and
myelodysplastic
syndromes
in
groups
B.Acta
Haematol
100:13-19,1998.
28. Breton-Gorious J, Houssay D, Dreyfus
B: Partial myeloperoidase deficiency in
a case of preleukaemia. I : Studied of
fine structures and peroidase synthesis
of
promyelocytes.
Br
Haematol
Pathol
30:273,1975.
29. Bauman MA, Keller RH, Mc Fadden
39:1233,1985.
23. Steensma DP, Gibbons RJ, Higgs DR :
myeloid
Acquired
leukaemia,
Chin
alpha-thalassemia
in
cell
surface
phenotype
in
of
an
early
myeloid
Thrombocytopathy in preleukaemia :
22:251, 1987.
30. Calark RE, Smith SA, Jacobs A :
1979.
37. Raman KS, Van Sylk EJ, Riddle J,
Platelet
J.Clin.Pathol 40:952,1987.
31. Hokland P, Kerndrup G, Griffin JD,
Ellegaard
J:
Analysis
of
leucocyte
function
and
myeloproliverative
structures
disease
myelodysplastic
syndromes
in
,
and
praleukaemia
bone
marrow
from
Haematol 91:912-917,1995.
39. Sorskaar D, Forre O, Alberstein D,
markers
in
mononuclear
cell
from
U:
Immunophenotipic characterization of
synthesis
myelodysplastic
syndromes
Majdic
O,
Ludwig
H,
Koller
syndromes.
Br
in
:
myelodisplastic
normal
cell
and
abnormalities
1994.
35. Felman P, Bryon PA, Gentilhomme O, et
1987.
42. Sauntararajah Y, Nakamura R, Nam JM
et
clumping
overpressented
in
myelodysplastic
leucocytes
disorder
a
with
al.:
in
myelodysplastic
HLA-DR15
in
(DR2)
is
myelodysplastic
predics
response
to
49-54, 1988.
immunosupression in myelodysplastic
syndromes.
Blood
100:1570-1574,
2002.
43. Mufti GJ, Figes A, Hamblin TJ, Oscier
DG,
Coppleston
abnormalities
T,
myelodysplastic
myelodysplastic
with
Immunological
JA:
in
patients
Economidou
J,
Giannopoulus
et
al.:
Immune
abnormalities
in
myelodysplastic
progenitor
for
human
myeloid
and
significance
features
of
blast
myelodysplastic
of
in
phenotype
patients
syndromes
with
Blood
100:3887-3899,2002.
53. Kasahara S, Hara T, Itoh H et al.:
Testi
C,
Bombardieri
Disease
with
S:
Bechets
gastrointestinal
involvement in myelodysplastic in a
patients
with
panhypopytuarysm.
Clin
al.:Glomerular
myelodysplastic
Rheumatol
myelodysplastic
involvement
syndromes.
AG,
immunophenotyping
98:391-392, 2002.
55. Stetler-Stevenson
syndromes.
M,
Arthur
in
Blood
DC,
in
Pediatri
syndromes.
Am
2002.
54. Eighetany MT: Diagnoostic utility of flow
cytometric
Nephrol 19:1053-1057,2001.
48. Saitoh T, Murakami, Uchiumi, et al.:
Myelodysplastic
congenital
17:515-517,1998.
47. Bagdanovic R, Kuzmanovic M, Markovic
et
Moutsopoulus
HM:
myelodysplastic
syndromes.
Blood
98:979-987, 2001.
56. Miller DT, Stezer GT: Contributions of
flow cytometry to the analysis of the
myelodysplastic syndromes . Clin Lab
in
prospective
Rheumatology
Autoimmune
phenomena
study.
acute
leukaemia
and
high
risk
bone
marrow
from
myelodysplastic
patients
syndromes.
with
Arch
features
of
disorders,
Leuk
with
BJ:
sideroblastic
syndromes.
Leuk
with
fibrosis:
distinc
increased
marrow
clinic-pathological
associated
with
bone
with
paroxysmal
nocturnal
syndrome.
3519,2001.
Blood
Diagnosis
and
syndrome.
Oncology
cytogenetic
abnormalities
in
433-440, 2004.
67. Paquette
RL:
98:3513-
lymphocytic
disease:
pathophysiological
clinical
features.
Haematol 112:195-200,2001.
and
Br